Jan. 08 LunchTime Movers Board: Ambrx Biopharma rockets 98% after reaching an acquisition agreement with JNJ
AInvestMonday, Jan 8, 2024 9:49 am ET
2min read

Seize the market opportunities with us at 8:45 every morning, and don't forget to check our "Lunchtime Movers Board" at 12:00.

LunchTime Gainers:Ambrx, Aclarion, Axonics, Cellectar, Vivos

AMAM:

AmbrxBiopharma rockets 98% after reaching an acquisition agreement with JNJ.

ACON:

Aclarion soars 81% after announcing partnership agreement with Alphatec Spine.

AXNX:

Axonics, Inc jumps 20% after Boston Scientific announced agreement to acquire the Co.

CLRB:

CellectarBioSciences surges 15% after announcing Positive topline data achieving primary endpoint in pivotal clinical study of Iopofosine I 131 in Waldenstrom"s macroglobulinemia.

VVOS:

VivosTherapeutics climbs 5% after seeing positive preliminary metrics following unprecedented FDA 510(k) clearance of the company"s proprietary oral medical devices to treat severe OSA.

LunchTime Losers:Solo, Dada, Prothena, Evolve, Zim

DTC:

SoloBrands stock plunges 32% after guidance cut.

DADA:

DadaNexus slumps 30% as the Co. found questionable conduct during routing internal audits.

PRTA:

Prothenaslumps 26% after providingupset updates on PRX012, PRX123, Birtamimab and portfolio programs.

SNMP:

EvolveTransitionInfrastructureslides 17% after reporting exercise of right to purchase common units.

ZIM:

ZimIntegratedShippingsinks 10% after China"s COSCO halted shipping to Israel.

$AMAM(AMAM)$ACON(ACON)$AXNX(AXNX)$CLRB(CLRB)$VVOS(VVOS)$DTC(DTC)$PRTA(PRTA)$SNMP(SNMP)$ZIM(ZIM)$DADA(DADA)

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.